• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Body and Mind Enters Agreement to Acquire Iconic Dispensary Chain in California

Share:

December 3, 2018

Body and Mind Inc. and Australis Capital Inc. are pleased to announce an investment by BaM into Green Light District Holdings, Inc. by way of a USD $5,200,000 senior secured convertible note at a rate equal to 20% per annum. The note is convertible into 89.75% of the shares of GLDH at the option of the Company. In addition, BaM has an agreement to issue additional consideration to David Barakett totalling USD $6,297,580 payable in shares of BaM at price of CAD $0.7439 upon meeting certain milestones. The price was calculated using a 5-day volume weighted average price as of November 28, 2018. BaM’s investment in GLDH was funded in part by a $4,000,000 secured loan from Australis.

GLDH is the owner of the well-known ShowGrow dispensary brand and owner of the ShowGrow Long Beach dispensary, 43% of the equity interest and 60% of the voting rights in the ShowGrow San Diego dispensary, 30% equity interest in ShowGrow Las Vegas, and 100% ownership of the popular ShowGrow app. The dispensaries are in various stages of licensing: Long Beach has a medical license, San Diego has a conditional use permit, and Las Vegas has a recreational license. GLDH focuses on building dispensaries in high volume locations and will continue to work toward receiving its recreational status at both Long Beach and San Diego. ShowGrow San Diego still requires build out and is not yet open for business.

The highlights of this transaction are as follows:

  • Provides a beachhead for BaM to establish operations in California, which will assist BaM in rolling out its brands beyond Nevada and Ohio;
  • Expands exposure to retail and provides BaM access to a seasoned retail management team that can also assist in adding value to the Ohio and Nevada platforms;
  • Provides exposure to high-growth, near-term revenue producing assets with solid earnings potential;
  • Provides additional optionality of new retail licensing via ShowGrow Nevada, which has applied for new retail licenses that could be awarded in early December;
  • Access to deep domain knowledge of the California cannabis industry, and a solid pipeline of deal flow; and
  • Provides shareholders first hand evidence of the strong relationship with Australis, which enabled BaM to capitalize on a timely opportunity.

Leonard Clough, BaM’s CEO commented, “Our gratitude goes to the team at Australis, who worked tirelessly in assisting us in getting this deal completed within a one-week period. Australis not only provided BaM with a secured credit facility, but also agreed to exercise approximately 3.2 million warrants to allow us to maintain a responsible debt to equity ratio. This is a demonstration of how the Australis and BaM relationship benefits both our shareholders. Secondly, I am happy to welcome David to our team and believe that this opportunity is multi-dimensional as it provides a benefit to almost all our business segments.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Scott Dowty, CEO of Australis commented, “We are consistently looking for high impact transactions that can assist our portfolio companies in creating outsized returns and the ShowGrow deal does exactly that for BaM. This deal provides BaM access to a tremendous market beyond Nevada and Ohio, and the ability to leverage the BaM brand further. David Barakett’s experience in the industry is also a great addition to an already strong management team at BaM. We will continue to support BaM in new deals while also identifying opportunities within our ecosystem that can further benefit BaM, our largest and most significant investment to date.”

Funding Agreements

To fund this transaction, Australis provided BaM a two-year USD $4,000,000 loan by way of a senior secured note bearing an interest rate of 15%. The terms require semi-annual interest payments unless BaM elects to accrue the interest by adding it to the principal amount of the debt facility. The Company will maintain prepayment rights at any time, in any amount, unless it is within the first year in which case the Company will be required to pay a 5% prepayment penalty on the amount repaid. The Company paid a finance fee to Australis in the amount of 1,105,083 BaM shares at a deemed price of CAD $0.72 per share.

In addition, Australis has agreed to exercise USD $1.2m in warrants out of the 16m warrants they already hold in BaM at CAD $0.50, which will equate to approximately 3.2m shares depending on the USD / CAD exchange rate when exercised. Australis will have 5 business days from the funding agreement dated November 28 [th] , 2018 to exercise its warrants in BaM.

As a result of this transaction, and the potential dilution associated with the Earn-Out Shares owed to David Barakett, who is entitled to receive shares in BaM subject to meeting certain performance milestones, the Company has granted anti-dilution warrants with a 2-year term from issuance to Australis at a ratio of 0.4337 for every share issued to David Barakett, at a price equal to the Earn-Out Shares or otherwise at the lowest price permitted under the policies of the Canadian Securities Exchange.

The Company also agreed to increase the monthly services fee to Australis to total $16,500 per month for 5 years unless ownership held by Australis drops below 10% in which the fee will cease.

Canaccord Genuity Corp. acted as financial advisor to BaM in connection with the Transaction.

Date: December 3, 2018

Source: Marketwatch

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • NexHealth Raises $4M In FundingNexHealth Raises $4M In Funding
  • Roche Pays $7.1B to Roivant for Rights to Telavant’s IBD CandidateRoche Pays $7.1B to Roivant for Rights to Telavant’s IBD Candidate
  • Mobile Assessment App PainChek Forays into Hospitals via InterSystems PartnershipMobile Assessment App PainChek Forays into Hospitals via InterSystems Partnership
  • AGC Enters Agreement to Acquire Synthetic Pharmaceutical Active Ingredient-manufacturing Plant in SpainAGC Enters Agreement to Acquire Synthetic Pharmaceutical Active Ingredient-manufacturing Plant in Spain
  • ILC Dover Acquires Solo Containment, a Leading UK-Based Provider of Products Used in Pharmaceutical and Biopharmaceutical ManufacturingILC Dover Acquires Solo Containment, a Leading UK-Based Provider of Products Used in Pharmaceutical and Biopharmaceutical Manufacturing
  • Wright Medical inks $435M takeover of implant firm CartivaWright Medical inks $435M takeover of implant firm Cartiva
  • EUSA Pharma announce acquisition of SYLVANT® from JanssenEUSA Pharma announce acquisition of SYLVANT® from Janssen
  • Exclusive Demand for Diabetic Neuropathic Pain Drug Market Projected to Witness Vigorous Expansion by 2020-2027 by Major innovators like Astellas Pharma, AstraZeneca PlcExclusive Demand for Diabetic Neuropathic Pain Drug Market Projected to Witness Vigorous Expansion by 2020-2027 by Major innovators like Astellas Pharma, AstraZeneca Plc

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications